Human Papillomavirus (HPV): A Study Analysis
HUMAN PAPILLOMAVIRUS (HPV): A STUDY ANALYSIS 2 Human Papillomavirus (HPV): A Study Analysis
Human papillomavirus infection (HPV) is the most frequent sexually transmitted disease. Eighty percent of HPV infection cases are cleared in a few months without treatment, but in the remaining 20%, the infection becomes persistent (Ribassin-Majed, Lounes, and Clémençon 2012, p. 1). Over 100 types of HPV have been identified: low-risk types, which are responsible for benign anogenital lesions (genital warts), and high-risk types, which can lead to precancerous and cancerous lesions in the cervix. Cervical cancer is the second most common cancer in women worldwide, but the most common in developing countries, where 80% of cases occur (Munoz et al., 2004, p. 278). By 2003, 7 of the most prevalent HPV genotypes causing 87% of cervical cancers were identified (Raffle, 2007, p.375). In 71% of the cases, HPV-16 genotype, HPV-18 genotype, or both were detected (Munoz et al., 2004, p. 280).
A bivalent vaccine (HPV-16/18) for HPV-16 and HPV-18 was presented to the IVB Strategic Advisory Group of Experts (SAGE) at its November 2005 meeting. SAGE noted that there might be communication challenges for a vaccine against a sexually transmitted disease and suggested that it might be helpful to study the impact of population screening in conjunction with the vaccine. They determined that there might be tremendous benefits from using a vaccine in settings with a high prevalence of cervical cancer, especially in countries where screening programs were limited or non-existent. In November
References: FUTURE II Study Group. (2007). Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. New England Journal of Medicine, 356, 1915-27. Milstien, J., Cardenas, V., Cheyne, J., & Brooks, A Raffle, A. (2007). Challenges of implementing human Papillomavirus (hpv) vaccination policy. British Medical Journal, 335(7616), 375-377. doi:10.1136/bmj.39273.458322.BE Ribassin-Majed, L., Lounes, R., & Clemencon, S Sanders, G. D., Taira, A. V. (2003). Cost Effectiveness of a Potential Vaccine for Human papillomavirus. Emerging Infectious Diseases, 9(1), 37-48.